Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17872140 | 0.89 | KLK7 (0.53) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL5996732 | 0.86 | CTSK (0.61) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL4857149 | 0.86 | MAPT (0.58) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL17872138 | 0.85 | MAPT (0.56) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL25502674 | 0.85 | MAPT (0.60) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL30902907 | 0.85 | MAPT (0.65) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL16124431 | 0.85 | MAPT (0.60) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL23626336 | 0.84 | CPB1 (0.67) | KLK7KLK5MAPTCPB1CPB2 | |
| SCHEMBL20543022 | 0.84 | SIRT2 (0.62) | KLK7KLK5MAPTCTSSCTSL | |
| SCHEMBL20543025 | 0.84 | SIRT2 (0.62) | KLK7KLK5MAPTCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | LUMIPHORE, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360956-A1 | FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF | CLTB, CLTA, EPCAM | KLK7 1145/4885KLK5 1322/4885MAPT 1163/4885 |
| US-10434186-B2 | Functionalized linear ligands and complexes thereof | CLTB, CLTA, EPCAM | KLK7 1145/4885KLK5 1322/4885MAPT 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.